Arbutus Biopharma Corp Stock Revenue
| ABUS Stock | USD 2.64 0.08 2.94% |
Arbutus Biopharma Corp fundamentals help investors to digest information that contributes to Arbutus Biopharma's financial success or failures. It also enables traders to predict the movement of Arbutus Stock. The fundamental analysis module provides a way to measure Arbutus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arbutus Biopharma stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 18.1 M | 12.7 M |
Arbutus | Revenue |
Arbutus Biopharma Corp Company Revenue Analysis
Arbutus Biopharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Arbutus Biopharma Revenue | 18.14 M |
Most of Arbutus Biopharma's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Arbutus
Projected quarterly revenue analysis of Arbutus Biopharma Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Arbutus Biopharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Arbutus Biopharma's stock price.
Arbutus Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Revenue. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
| 0.59 | -0.59 | 0.49 | -0.35 | 0.33 | ||
| 0.59 | -0.4 | 0.54 | 0.21 | 0.38 | ||
| -0.59 | -0.4 | -0.19 | -0.21 | -0.39 | ||
| 0.49 | 0.54 | -0.19 | 0.17 | 0.68 | ||
| -0.35 | 0.21 | -0.21 | 0.17 | 0.29 | ||
| 0.33 | 0.38 | -0.39 | 0.68 | 0.29 |
Click cells to compare fundamentals
Arbutus Revenue Historical Pattern
Today, most investors in Arbutus Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arbutus Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Arbutus Biopharma revenue as a starting point in their analysis.
Arbutus Biopharma Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Arbutus Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Arbutus Biopharma Corp reported 18.14 M of revenue. This is 99.76% lower than that of the Biotechnology sector and 97.56% lower than that of the Health Care industry. The revenue for all United States stocks is 99.81% higher than that of the company.
Arbutus Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arbutus Biopharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics of similar companies.Arbutus Biopharma is currently under evaluation in revenue category among related companies.
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 158.7M | 269.2M | 413.3M | 351.7M | 414.9M | 435.6M | |
| Enterprise Value | 130.3M | 219.9M | 306.6M | 323.1M | 397.3M | 417.2M |
Arbutus Biopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Arbutus Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arbutus Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arbutus Biopharma's value.| Shares | Millennium Management Llc | 2023-12-31 | 1.5 M | Centiva Capital, Lp | 2023-12-31 | 1.4 M | Advisor Group Holdings, Inc. | 2023-12-31 | 1.4 M | Fourworld Capital Management Llc | 2023-12-31 | 1.1 M | Northern Trust Corp | 2023-12-31 | 1.1 M | Assenagon Asset Management Sa | 2023-12-31 | 817.6 K | Bank Of New York Mellon Corp | 2023-12-31 | 456.8 K | Boothbay Fund Management, Llc | 2023-12-31 | 453.6 K | Kennedy Capital Management Inc | 2023-12-31 | 387.2 K | Whitefort Capital Management, Lp. | 2023-12-31 | 13.2 M | Blackrock Inc | 2023-12-31 | 10.4 M |
Arbutus Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (9.57) % | ||||
| Current Valuation | 370.94 M | ||||
| Shares Outstanding | 180.18 M | ||||
| Shares Owned By Insiders | 23.34 % | ||||
| Shares Owned By Institutions | 43.90 % | ||||
| Number Of Shares Shorted | 4.55 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 4.95 X | ||||
| Price To Sales | 28.90 X | ||||
| Revenue | 18.14 M | ||||
| Gross Profit | (45.39 M) | ||||
| EBITDA | (76.63 M) | ||||
| Net Income | (72.85 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 8.72 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | (85.94 M) | ||||
| Short Ratio | 7.05 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 4.4 | ||||
| Number Of Employees | 73 | ||||
| Beta | 2.09 | ||||
| Market Capitalization | 490.08 M | ||||
| Total Asset | 144.4 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 109.54 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arbutus Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arbutus Biopharma's short interest history, or implied volatility extrapolated from Arbutus Biopharma options trading.
Pair Trading with Arbutus Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Arbutus Stock
| 0.59 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
| 0.51 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.43 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.41 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Arbutus Biopharma Piotroski F Score and Arbutus Biopharma Altman Z Score analysis. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.